A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

Mitsuhito Sasaki, Hideki Ueno, Shuichi Mitsunaga, Akihiro Ohba, Hiroko Hosoi, Satoshi Kobayashi, Makoto Ueno, Tetsuji Terazawa, Masahiro Goto, Dai Inoue, Shin Namiki, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Masafumi Ikeda, Takuji Okusaka, Mitsuhito Sasaki, Hideki Ueno, Shuichi Mitsunaga, Akihiro Ohba, Hiroko Hosoi, Satoshi Kobayashi, Makoto Ueno, Tetsuji Terazawa, Masahiro Goto, Dai Inoue, Shin Namiki, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Masafumi Ikeda, Takuji Okusaka

Abstract

Background: Although FOLFIRINOX is currently one of the standard therapies for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC), the high rate of febrile neutropenia (FN) presents a clinical problem. This study aimed to evaluate the safety and efficacy of primary prophylactic pegfilgrastim with FOLFIRINOX in Japanese MPC patients.

Methods: FOLFIRINOX (intravenous oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, levofolinate 200 mg/m2, 5-fluorouracil (5-FU) bolus 400 mg/m2 and 5-FU 46 h infusion 2400 mg/m2) and pegfilgrastim 3.6 mg on day 4 or 5, every 2 weeks was administered to previously untreated MPC patients. The primary endpoint was the incidence of FN during the first 3 cycles. The planned sample size was 35 patients, but the trial was predefined to discontinue enrollment for safety if 4 patients developed FN.

Results: At the enrollment of 22 patients, 4 patients developed FN in the first cycle, resulting in an incidence of FN of 18% {95% confidence interval [CI], 0.5-40.3%}, and enrollment was discontinued early. The incidence of grade 3 or higher neutropenia was 36.4%. Median relative dose intensities during the initial 3 cycles of oxaliplatin, irinotecan, bolus 5-FU, infusional 5-FU, and levofolinate maintained high (100%, 89.0%, 100%, 66.0%, and 100%, respectively). Response rate and median overall survival were 54.5% (95% CI 32.7-74.9) and 15.7 months (95% CI 7.9-18.8), respectively.

Conclusions: This phase II study could not demonstrate any reduction in the incidence of FN, nevertheless some patients experience benefits for efficacy by maintaining dose intensity using prophylactic pegfilgrastim.

Trial registration: http://www.umin.ac.jp/ctr/index-j.htm , UMIN000017538. Date of registration: May/13/2015.

Keywords: FOLFIRINOX; Febrile neutropenia; Pancreatic cancer; Pegfilgrastim.

Conflict of interest statement

M. Ueno has received honoraria for speaking and research grants from Yakult Honsha and Taiho Pharmaceutical; C. Morizane has received research grants from Yakult Honsha and Taiho Pharmaceutical; M. Ikeda has received honoraria for speaking from Taiho Pharmaceutical and research grants from Yault Honsha; S. Mitsunaga has received honoraria for speaking from Pfizer Japan and research grants from Taiho Pharmaceutical; Y. Sakamoto has received research grants from Takeda Pharmaceutical; M. Sasaki, H. Ueno, A. Ohba, H. Hosoi, S. Kobayashi, T. Terazawa, M. Goto, D. Inoue, S. Namiki, S. Kondo and T. Okusaka have no conflict of interest to declare.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Kaplan–Meier estimate of overall survival
Fig. 2
Fig. 2
Kaplan–Meier estimate of progression-free survival

References

    1. Vital Statistics Japan (Ministry of Health, Labour and Welfare) [Center for Cancer Control and Information Services, National Cancer Center, Japan Web site]. Available at: . Accessed Jan 2020
    1. Conroy T, Desseigne F, Ychou MO, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825. doi: 10.1056/NEJMoa1011923.
    1. Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–1326. doi: 10.1111/cas.12501.
    1. Hasegawa Y, Kawaguchi T, Kubo A, et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol. 2011;6:1881–1888. doi: 10.1097/JTO.0b013e31822722b6.
    1. Gandara DR, Kasaguchi T, Crowlet J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27:3540–3546. doi: 10.1200/JCO.2008.20.8793.
    1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170. doi: 10.1056/NEJM199107183250305.
    1. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer. A multicenter, double-blind, placebo controlled phase III study. J Clin Oncol. 2005;23:1178–1184. doi: 10.1200/JCO.2005.09.102.
    1. Aapro MS, Bohlius J, Cameron DA, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. doi: 10.1016/j.ejca.2010.10.013.
    1. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–3212. doi: 10.1200/JCO.2015.62.3488.
    1. National Comprehensive Cancer Network. NCCN® Clinical practice guidelines in oncology: myeloid growth factors, version 2.2020. National Comprehensive Cancer Network. Available at: . Accessed Jan 2020
    1. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35. doi: 10.1093/annonc/mdg019.
    1. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24(10):2475–2484. doi: 10.1093/annonc/mdt226.
    1. Keum J, Lee HS, Kang H, et al. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2020;85(4):651–659. doi: 10.1007/s00280-020-04051-x.
    1. Sasaki M, Ueno H, Kuchiba A, et al. Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment. Ann Oncol. 2015;26:iv1–iv100.
    1. Lee M, Yee J, Kim JY, et al. Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim. Asia Pac J Clin Oncol. 2019;15(4):231–237.
    1. Havrilesky LJ, Reiner M, Morrow PK, et al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93:203–210. doi: 10.1016/j.critrevonc.2014.10.006.
    1. Luciani A, Bertuzzi C, Ascione G, et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2009;66:94–96. doi: 10.1016/j.lungcan.2008.12.019.
    1. Loibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of relative total dose intensity (RTDI) on patients’ short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer. 2011;11:131. doi: 10.1186/1471-2407-11-131.
    1. Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129:74–80. doi: 10.1016/j.ygyno.2012.12.017.
    1. Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer. 2017;76:125–133. doi: 10.1016/j.ejca.2017.02.010.
    1. Kobayashi S, Ueno M, Omae K, et al. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Oncotarget. 2019;10(19):1775–1784. doi: 10.18632/oncotarget.26633.
    1. Ozaka M, Ishii H, Sato T, et al. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2018;81(6):1017–1023. doi: 10.1007/s00280-018-3577-9.
    1. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42(8):1311–1315. doi: 10.1097/MPA.0b013e31829e2006.
    1. Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114(7):737–743. doi: 10.1038/bjc.2016.45.
    1. Kajiyama K, Ishiguro C, Ando T, et al. Nested case-control study utilizing MID-NET® on thrombocytopenia associated with pegfilgrastim in patients treated with antineoplastic agents. Clin Pharmacol Ther. 2021 doi: 10.1002/cpt.2263.
    1. Masuda N, Tokuda Y, Nakamura S, et al. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer. 2015;23(10):2891–2898. doi: 10.1007/s00520-015-2654-4.
    1. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–548. doi: 10.1634/theoncologist.2012-0435.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe